Citable filing context
ISRG's research view summarizes recent SEC filing context, starting with other from Jul 27, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 27, 2026 | other | Intuitive Surgical amended its bylaws to update shareholder meeting procedures, director nominations, and proxy solicitation requirements. |
| Jul 16, 2026 | earnings | Intuitive Surgical reported Q2 2026 revenue of $2.89 billion and net income of $818 million. |
| May 28, 2026 | management_change | Intuitive Surgical appointed Taylor Patton as Chief Commercial and Marketing Officer, succeeding Henry Charlton, effective July 1, 2026. |
| Jul 16, 2026 | Guidance: non_gaap_gross_profit_margin | 68.00 to 69.00 |
| Jul 16, 2026 | Guidance: non_gaap_operating_expense_growth | 11.00 to 13.00 |
| Jul 16, 2026 | Guidance: worldwide_da_vinci_procedure_growth | 13.50 to 15.50 |
| Jul 21, 2026 | mda_quarterly | Intuitive Surgical reported strong second-quarter 2026 results, with total revenue rising 19% to $2.89 billion. Growth was driven by a 15% increase in da Vinci procedure volumes and a 36% surge in Ion endoluminal procedures. The company’s installed base reached 11,710 da Vinci systems and 1,096 Ion systems. Financial performance benefited from favorable product mix, particularly the adoption of the fifth-generation da Vinci 5 system, which saw 246 placements in the quarter. Management highlighted significant macroeconomic and geopolitical risks, including inflationary pressures, supply chain constraints, and elevated interest rates, which continue to impact hospital capital spending. In China, competitive pressure from domestic manufacturers and a government-led governance campaign have delayed or canceled hospital tenders, resulting in fewer system placements than anticipated. Additionally, the company is navigating a complex tariff environment; while it received $35.9 million in IEEPA-related refunds during the quarter, it remains exposed to potential cost inflation from retaliatory trade measures and semiconductor supply volatility. Despite these headwinds, Intuitive maintains a robust liquidity position with $8.63 billion in cash and investments, supporting ongoing R&D investments and share repurchases. The company continues to expand its leasing model, which now accounts for a larger proportion of system placements. |
| Apr 22, 2026 | mda_quarterly | Intuitive Surgical reported robust first quarter 2026 results, with total revenue increasing 23% to $2.77 billion. This growth was fueled by a 16% rise in da Vinci procedures, reaching 847,000, and a 39% surge in Ion endoluminal procedures to 42,700. Instruments and accessories revenue climbed 23%, while systems revenue grew 24%, reflecting strong demand for the new da Vinci 5 system, which accounted for 232 of the 431 da Vinci systems placed. The installed base expanded to 11,395 da Vinci and 1,041 Ion systems. U.S. da Vinci procedure growth (14%) was driven by general surgery and gynecology, while OUS procedures (19%) saw significant adoption in Europe and Asia, notably India, UK, South Korea, Italy, and Germany. Japan also secured reimbursement for seven additional da Vinci procedures. However, China's market faced headwinds from increased competition and a government governance campaign, leading to fewer system placements and pricing pressure on instruments. Macroeconomic factors, including $28 million in tariff expenses, inflation, and high interest rates, continue to impact hospital capital spending and supply chains. The company is actively expanding indications and global clearances for its da Vinci 5 and da Vinci SP systems, with leasing models comprising a significant portion of system placements. |
Source: SEC EDGAR filing text and events; period Jul 27, 2026; filed Jul 27, 2026.
ISRG company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.